<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39405332</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>25</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>27</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1553-7374</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Oct</Month></PubDate></JournalIssue><Title>PLoS pathogens</Title><ISOAbbreviation>PLoS Pathog</ISOAbbreviation></Journal><ArticleTitle>Characterisation of the antibody-mediated selective pressure driving intra-host evolution of SARS-CoV-2 in prolonged infection.</ArticleTitle><Pagination><StartPage>e1012624</StartPage><MedlinePgn>e1012624</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e1012624</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.ppat.1012624</ELocationID><Abstract><AbstractText>Neutralising antibodies against the SARS-CoV-2 spike (S) protein are major determinants of protective immunity, though insufficient antibody responses may cause the emergence of escape mutants. We studied the humoral immune response causing intra-host evolution in a B-cell depleted, haemato-oncologic patient experiencing clinically severe, prolonged SARS-CoV-2 infection with a virus of lineage B.1.177.81. Following bamlanivimab treatment at an early stage of infection, the patient developed a bamlanivimab-resistant mutation, S:S494P. After five weeks of apparent genetic stability, the emergence of additional substitutions and deletions within the N-terminal domain (NTD) and the receptor binding domain (RBD) of S was observed. Notably, the composition and frequency of escape mutations changed in a short period with an unprecedented dynamic. The triple mutant S:Delta141-4 E484K S494P became dominant until virus elimination. Routine serology revealed no evidence of an antibody response in the patient. A detailed analysis of the variant-specific immune response by pseudotyped virus neutralisation test, surrogate virus neutralisation test, and immunoglobulin-capture enzyme immunoassay showed that the onset of an IgM-dominated antibody response coincided with the appearance of escape mutations. The formation of neutralising antibodies against S:Delta141-4 E484K S494P correlated with virus elimination. One year later, the patient experienced clinically mild re-infection with Omicron BA.1.18, which was treated with sotrovimab and resulted in an increase in Omicron-reactive antibodies. In conclusion, the onset of an IgM-dominated endogenous immune response in an immunocompromised patient coincided with the appearance of additional mutations in the NTD and RBD of S in a bamlanivimab-resistant virus. Although virus elimination was ultimately achieved, this humoral immune response escaped detection by routine diagnosis and created a situation temporarily favouring the rapid emergence of various antibody escape mutants with known epidemiological relevance.</AbstractText><CopyrightInformation>Copyright: © 2024 Schoefbaenker et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schoefbaenker</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Virology Muenster, University of Muenster, Muenster, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Günther</LastName><ForeName>Theresa</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Institute of Virology Muenster, University of Muenster, Muenster, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lorentzen</LastName><ForeName>Eva Ulla</ForeName><Initials>EU</Initials><AffiliationInfo><Affiliation>Institute of Virology Muenster, University of Muenster, Muenster, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Romberg</LastName><ForeName>Marie-Luise</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Institute of Virology Muenster, University of Muenster, Muenster, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hennies</LastName><ForeName>Marc Tim</ForeName><Initials>MT</Initials><AffiliationInfo><Affiliation>Institute of Virology Muenster, University of Muenster, Muenster, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Neddermeyer</LastName><ForeName>Rieke</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Institute of Virology Muenster, University of Muenster, Muenster, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Müller</LastName><ForeName>Marlin Maybrit</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Institute of Virology Muenster, University of Muenster, Muenster, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mellmann</LastName><ForeName>Alexander</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Hygiene, University Hospital Muenster, University of Muenster, Muenster, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bojarzyn</LastName><ForeName>Chiara Robin</ForeName><Initials>CR</Initials><AffiliationInfo><Affiliation>Institute of Virology Muenster, University of Muenster, Muenster, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lenz</LastName><ForeName>Georg</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Medicine A, Haematology, Oncology and Pneumology, University Hospital Muenster, Muenster, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stelljes</LastName><ForeName>Matthias</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Medicine A, Haematology, Oncology and Pneumology, University Hospital Muenster, Muenster, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hrincius</LastName><ForeName>Eike Roman</ForeName><Initials>ER</Initials><AffiliationInfo><Affiliation>Institute of Virology Muenster, University of Muenster, Muenster, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vollenberg</LastName><ForeName>Richard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Medicine B for Gastroenterology, Hepatology, Endocrinology and Clinical Infectiology, University Hospital Muenster, Muenster, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ludwig</LastName><ForeName>Stephan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute of Virology Muenster, University of Muenster, Muenster, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tepasse</LastName><ForeName>Phil-Robin</ForeName><Initials>PR</Initials><AffiliationInfo><Affiliation>Department of Medicine B for Gastroenterology, Hepatology, Endocrinology and Clinical Infectiology, University Hospital Muenster, Muenster, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kühn</LastName><ForeName>Joachim Ewald</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>Institute of Virology Muenster, University of Muenster, Muenster, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D002363">Case Reports</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS Pathog</MedlineTA><NlmUniqueID>101238921</NlmUniqueID><ISSNLinking>1553-7366</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000657845">spike protein, SARS-CoV-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>45I6OFJ8QH</RegistryNumber><NameOfSubstance UI="C000711749">bamlanivimab</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Organism" UI="C000711908">SARS-CoV-2 variants</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="Y">Antibodies, Viral</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064370" MajorTopicYN="Y">Spike Glycoprotein, Coronavirus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="Y">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061067" MajorTopicYN="Y">Antibodies, Monoclonal, Humanized</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="N">COVID-19 Drug Treatment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056724" MajorTopicYN="N">Immunity, Humoral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>2</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>10</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>25</Day><Hour>22</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>15</Day><Hour>22</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>15</Day><Hour>13</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39405332</ArticleId><ArticleId IdType="pmc">PMC11508484</ArticleId><ArticleId IdType="doi">10.1371/journal.ppat.1012624</ArticleId><ArticleId IdType="pii">PPATHOGENS-D-24-00273</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Roemer C, Sheward DJ, Hisner R, Gueli F, Sakaguchi H, Frohberg N, et al.. SARS-CoV-2 evolution in the Omicron era. Nature Microbiology. 2023;8(11):1952–9. doi: 10.1038/s41564-023-01504-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41564-023-01504-w</ArticleId><ArticleId IdType="pubmed">37845314</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao Y, Jian F, Wang J, Yu Y, Song W, Yisimayi A, et al.. Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution. Nature. 2023;614(7948):521–9. doi: 10.1038/s41586-022-05644-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-05644-7</ArticleId><ArticleId IdType="pmc">PMC9931576</ArticleId><ArticleId IdType="pubmed">36535326</ArticleId></ArticleIdList></Reference><Reference><Citation>Team C-F. Past SARS-CoV-2 infection protection against re-infection: a systematic review and meta-analysis. Lancet. 2023;401(10379):833–42. doi: 10.1016/S0140-6736(22)02465-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)02465-5</ArticleId><ArticleId IdType="pmc">PMC9998097</ArticleId><ArticleId IdType="pubmed">36930674</ArticleId></ArticleIdList></Reference><Reference><Citation>Lapuente D, Winkler TH, Tenbusch M. B-cell and antibody responses to SARS-CoV-2: infection, vaccination, and hybrid immunity. Cell Mol Immunol. 2024;21(2):144–58. doi: 10.1038/s41423-023-01095-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41423-023-01095-w</ArticleId><ArticleId IdType="pmc">PMC10805925</ArticleId><ArticleId IdType="pubmed">37945737</ArticleId></ArticleIdList></Reference><Reference><Citation>Braun KM, Moreno GK, Wagner C, Accola MA, Rehrauer WM, Baker DA, et al.. Acute SARS-CoV-2 infections harbor limited within-host diversity and transmit via tight transmission bottlenecks. PLoS Pathog. 2021;17(8):e1009849. doi: 10.1371/journal.ppat.1009849</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1009849</ArticleId><ArticleId IdType="pmc">PMC8412271</ArticleId><ArticleId IdType="pubmed">34424945</ArticleId></ArticleIdList></Reference><Reference><Citation>Lythgoe KA, Hall M, Ferretti L, de Cesare M, MacIntyre-Cockett G, Trebes A, et al.. SARS-CoV-2 within-host diversity and transmission. Science. 2021;372(6539). doi: 10.1126/science.abg0821</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abg0821</ArticleId><ArticleId IdType="pmc">PMC8128293</ArticleId><ArticleId IdType="pubmed">33688063</ArticleId></ArticleIdList></Reference><Reference><Citation>Markov PV, Ghafari M, Beer M, Lythgoe K, Simmonds P, Stilianakis NI, et al.. The evolution of SARS-CoV-2. Nature Reviews Microbiology. 2023;21(6):361–79. doi: 10.1038/s41579-023-00878-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-023-00878-2</ArticleId><ArticleId IdType="pubmed">37020110</ArticleId></ArticleIdList></Reference><Reference><Citation>Cele S, Karim F, Lustig G, San JE, Hermanus T, Tegally H, et al.. SARS-CoV-2 prolonged infection during advanced HIV disease evolves extensive immune escape. Cell Host Microbe. 2022;30(2):154–62 e5. doi: 10.1016/j.chom.2022.01.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2022.01.005</ArticleId><ArticleId IdType="pmc">PMC8758318</ArticleId><ArticleId IdType="pubmed">35120605</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaguza C, Hahn AM, Petrone ME, Zhou S, Ferguson D, Breban MI, et al.. Accelerated SARS-CoV-2 intrahost evolution leading to distinct genotypes during chronic infection. Cell Reports Medicine. 2023;4(2):100943. doi: 10.1016/j.xcrm.2023.100943</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2023.100943</ArticleId><ArticleId IdType="pmc">PMC9906997</ArticleId><ArticleId IdType="pubmed">36791724</ArticleId></ArticleIdList></Reference><Reference><Citation>Boshier FAT, Pang J, Penner J, Parker M, Alders N, Bamford A, et al.. Evolution of viral variants in remdesivir-treated and untreated SARS-CoV-2-infected pediatrics patients. J Med Virol. 2022;94(1):161–72. doi: 10.1002/jmv.27285</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27285</ArticleId><ArticleId IdType="pmc">PMC8426849</ArticleId><ArticleId IdType="pubmed">34415583</ArticleId></ArticleIdList></Reference><Reference><Citation>Corey L, Beyrer C, Cohen MS, Michael NL, Bedford T, Rolland M. SARS-CoV-2 Variants in Patients with Immunosuppression. N Engl J Med. 2021;385(6):562–6. doi: 10.1056/NEJMsb2104756</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMsb2104756</ArticleId><ArticleId IdType="pmc">PMC8494465</ArticleId><ArticleId IdType="pubmed">34347959</ArticleId></ArticleIdList></Reference><Reference><Citation>Dioverti V, Salto-Alejandre S, Haidar G. Immunocompromised Patients with Protracted COVID-19: a Review of "Long Persisters". Curr Transplant Rep. 2022;9(4):209–18. doi: 10.1007/s40472-022-00385-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40472-022-00385-y</ArticleId><ArticleId IdType="pmc">PMC9660019</ArticleId><ArticleId IdType="pubmed">36407883</ArticleId></ArticleIdList></Reference><Reference><Citation>Harari S, Tahor M, Rutsinsky N, Meijer S, Miller D, Henig O, et al.. Drivers of adaptive evolution during chronic SARS-CoV-2 infections. Nat Med. 2022;28(7):1501–8. doi: 10.1038/s41591-022-01882-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01882-4</ArticleId><ArticleId IdType="pmc">PMC9307477</ArticleId><ArticleId IdType="pubmed">35725921</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee CY, Shah MK, Hoyos D, Solovyov A, Douglas M, Taur Y, et al.. Prolonged SARS-CoV-2 Infection in Patients with Lymphoid Malignancies. Cancer Discov. 2022;12(1):62–73. doi: 10.1158/2159-8290.CD-21-1033</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/2159-8290.CD-21-1033</ArticleId><ArticleId IdType="pmc">PMC8758535</ArticleId><ArticleId IdType="pubmed">34753749</ArticleId></ArticleIdList></Reference><Reference><Citation>Machkovech HM, Hahn AM, Garonzik Wang J, Grubaugh ND, Halfmann PJ, Johnson MC, et al.. Persistent SARS-CoV-2 infection: significance and implications. Lancet Infect Dis. 2024. doi: 10.1016/S1473-3099(23)00815-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(23)00815-0</ArticleId><ArticleId IdType="pubmed">38340735</ArticleId></ArticleIdList></Reference><Reference><Citation>Voloch CM, da Silva Francisco R Jr, de Almeida LGP, Brustolini OJ, Cardoso CC, Gerber AL, et al.. Intra-host evolution during SARS-CoV-2 prolonged infection. Virus Evol. 2021;7(2):veab078. doi: 10.1093/ve/veab078</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ve/veab078</ArticleId><ArticleId IdType="pmc">PMC8500031</ArticleId><ArticleId IdType="pubmed">34642605</ArticleId></ArticleIdList></Reference><Reference><Citation>Meiring S, Tempia S, Bhiman JN, Buys A, Kleynhans J, Makhasi M, et al.. Prolonged Shedding of Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at High Viral Loads Among Hospitalized Immunocompromised Persons Living With Human Immunodeficiency Virus (HIV), South Africa. Clin Infect Dis. 2022;75(1):e144–e56. doi: 10.1093/cid/ciac077</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac077</ArticleId><ArticleId IdType="pmc">PMC8903337</ArticleId><ArticleId IdType="pubmed">35134129</ArticleId></ArticleIdList></Reference><Reference><Citation>Raglow Z, Surie D, Chappell JD, Zhu Y, Martin ET, Kwon JH, et al.. SARS-CoV-2 shedding and evolution in patients who were immunocompromised during the omicron period: a multicentre, prospective analysis. Lancet Microbe. 2024. doi: 10.1016/S2666-5247(23)00336-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2666-5247(23)00336-1</ArticleId><ArticleId IdType="pubmed">38286131</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Choudhary MC, Regan J, Boucau J, Nathan A, Speidel T, et al.. SARS-CoV-2 viral clearance and evolution varies by type and severity of immunodeficiency. Sci Transl Med. 2024;16(731):eadk1599. doi: 10.1126/scitranslmed.adk1599</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.adk1599</ArticleId><ArticleId IdType="pmc">PMC10982957</ArticleId><ArticleId IdType="pubmed">38266109</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghafari M, Hall M, Golubchik T, Ayoubkhani D, House T, MacIntyre-Cockett G, et al.. Prevalence of persistent SARS-CoV-2 in a large community surveillance study. Nature. 2024;626(8001):1094–101. doi: 10.1038/s41586-024-07029-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-024-07029-4</ArticleId><ArticleId IdType="pmc">PMC10901734</ArticleId><ArticleId IdType="pubmed">38383783</ArticleId></ArticleIdList></Reference><Reference><Citation>Landis JT, Moorad R, Pluta LJ, Caro-Vegas C, McNamara RP, Eason AB, et al.. Intra-Host Evolution Provides for the Continuous Emergence of SARS-CoV-2 Variants. mBio. 2023;14(2):e0344822. doi: 10.1128/mbio.03448-22</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mbio.03448-22</ArticleId><ArticleId IdType="pmc">PMC10127995</ArticleId><ArticleId IdType="pubmed">36786605</ArticleId></ArticleIdList></Reference><Reference><Citation>Shapira G, Patalon T, Gazit S, Shomron N. Immunosuppression as a Hub for SARS-CoV-2 Mutational Drift. Viruses. 2023;15(4). doi: 10.3390/v15040855</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v15040855</ArticleId><ArticleId IdType="pmc">PMC10145566</ArticleId><ArticleId IdType="pubmed">37112835</ArticleId></ArticleIdList></Reference><Reference><Citation>McMahan K, Yu J, Mercado NB, Loos C, Tostanoski LH, Chandrashekar A, et al.. Correlates of protection against SARS-CoV-2 in rhesus macaques. Nature. 2021;590(7847):630–4. doi: 10.1038/s41586-020-03041-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-03041-6</ArticleId><ArticleId IdType="pmc">PMC7906955</ArticleId><ArticleId IdType="pubmed">33276369</ArticleId></ArticleIdList></Reference><Reference><Citation>Krammer F. A correlate of protection for SARS-CoV-2 vaccines is urgently needed. Nature Medicine. 2021;27(7):1147–8. doi: 10.1038/s41591-021-01432-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01432-4</ArticleId><ArticleId IdType="pubmed">34239135</ArticleId></ArticleIdList></Reference><Reference><Citation>Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al.. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nature Medicine. 2021;27(7):1205–11. doi: 10.1038/s41591-021-01377-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01377-8</ArticleId><ArticleId IdType="pubmed">34002089</ArticleId></ArticleIdList></Reference><Reference><Citation>Meijers M, Ruchnewitz D, Eberhardt J, Łuksza M, Lässig M. Population immunity predicts evolutionary trajectories of SARS-CoV-2. Cell. 2023. doi: 10.1016/j.cell.2023.09.022</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2023.09.022</ArticleId><ArticleId IdType="pmc">PMC10964984</ArticleId><ArticleId IdType="pubmed">37875109</ArticleId></ArticleIdList></Reference><Reference><Citation>Gruell H, Vanshylla K, Weber T, Barnes CO, Kreer C, Klein F. Antibody-mediated neutralization of SARS-CoV-2. Immunity. 2022;55(6):925–44. doi: 10.1016/j.immuni.2022.05.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2022.05.005</ArticleId><ArticleId IdType="pmc">PMC9118976</ArticleId><ArticleId IdType="pubmed">35623355</ArticleId></ArticleIdList></Reference><Reference><Citation>Dejnirattisai W, Zhou D, Ginn HM, Duyvesteyn HME, Supasa P, Case JB, et al.. The antigenic anatomy of SARS-CoV-2 receptor binding domain. Cell. 2021;184(8):2183–200 e22. doi: 10.1016/j.cell.2021.02.032</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.02.032</ArticleId><ArticleId IdType="pmc">PMC7891125</ArticleId><ArticleId IdType="pubmed">33756110</ArticleId></ArticleIdList></Reference><Reference><Citation>Suryadevara N, Shrihari S, Gilchuk P, Vanblargan LA, Binshtein E, Zost SJ, et al.. Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein. Cell. 2021;184(9):2316–31.e15. doi: 10.1016/j.cell.2021.03.029</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.03.029</ArticleId><ArticleId IdType="pmc">PMC7962591</ArticleId><ArticleId IdType="pubmed">33773105</ArticleId></ArticleIdList></Reference><Reference><Citation>Harari S, Miller D, Fleishon S, Burstein D, Stern A. Using big sequencing data to identify chronic SARS-Coronavirus-2 infections. Nat Commun. 2024;15(1):648. doi: 10.1038/s41467-024-44803-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-024-44803-4</ArticleId><ArticleId IdType="pmc">PMC10799923</ArticleId><ArticleId IdType="pubmed">38245511</ArticleId></ArticleIdList></Reference><Reference><Citation>King SM, Bryan SP, Hilchey SP, Wang J, Zand MS. First Impressions Matter: Immune Imprinting and Antibody Cross-Reactivity in Influenza and SARS-CoV-2. Pathogens. 2023;12(2):169. doi: 10.3390/pathogens12020169</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pathogens12020169</ArticleId><ArticleId IdType="pmc">PMC9967769</ArticleId><ArticleId IdType="pubmed">36839441</ArticleId></ArticleIdList></Reference><Reference><Citation>Painter MM, Johnston TS, Lundgreen KA, Santos JJS, Qin JS, Goel RR, et al.. Prior vaccination promotes early activation of memory T cells and enhances immune responses during SARS-CoV-2 breakthrough infection. Nat Immunol. 2023;24(10):1711–24. doi: 10.1038/s41590-023-01613-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-023-01613-y</ArticleId><ArticleId IdType="pubmed">37735592</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao Y, Wang J, Jian F, Xiao T, Song W, Yisimayi A, et al.. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nature. 2022;602(7898):657–63. doi: 10.1038/s41586-021-04385-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-04385-3</ArticleId><ArticleId IdType="pmc">PMC8866119</ArticleId><ArticleId IdType="pubmed">35016194</ArticleId></ArticleIdList></Reference><Reference><Citation>Reynolds CJ, Pade C, Gibbons JM, Otter AD, Lin KM, Munoz Sandoval D, et al.. Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure. Science. 2022;377(6603):eabq1841. doi: 10.1126/science.abq1841</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abq1841</ArticleId><ArticleId IdType="pmc">PMC9210451</ArticleId><ArticleId IdType="pubmed">35699621</ArticleId></ArticleIdList></Reference><Reference><Citation>Wise J. Covid-19: Omicron infection is poor booster to immunity, study finds. BMJ. 2022:o1474. doi: 10.1136/bmj.o1474</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.o1474</ArticleId><ArticleId IdType="pubmed">35705220</ArticleId></ArticleIdList></Reference><Reference><Citation>Schoefbaenker M, Neddermeyer R, Guenther T, Mueller MM, Romberg M-L, Classen N, et al.. Surrogate Virus Neutralisation Test Based on Nanoluciferase-Tagged Antigens to Quantify Inhibitory Antibodies against SARS-CoV-2 and Characterise Omicron-Specific Reactivity in a Vaccination Cohort. Vaccines. 2023;11(12):1832. doi: 10.3390/vaccines11121832</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines11121832</ArticleId><ArticleId IdType="pmc">PMC10748151</ArticleId><ArticleId IdType="pubmed">38140236</ArticleId></ArticleIdList></Reference><Reference><Citation>Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, et al.. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill. 2020;25(3). doi: 10.2807/1560-7917.ES.2020.25.3.2000045</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2020.25.3.2000045</ArticleId><ArticleId IdType="pmc">PMC6988269</ArticleId><ArticleId IdType="pubmed">31992387</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, et al.. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579(7798):265–9. doi: 10.1038/s41586-020-2008-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2008-3</ArticleId><ArticleId IdType="pmc">PMC7094943</ArticleId><ArticleId IdType="pubmed">32015508</ArticleId></ArticleIdList></Reference><Reference><Citation>von Rhein C, Scholz T, Henss L, Kronstein-Wiedemann R, Schwarz T, Rodionov RN, et al.. Comparison of potency assays to assess SARS-CoV-2 neutralizing antibody capacity in COVID-19 convalescent plasma. J Virol Methods. 2021;288:114031. doi: 10.1016/j.jviromet.2020.114031</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jviromet.2020.114031</ArticleId><ArticleId IdType="pmc">PMC7707675</ArticleId><ArticleId IdType="pubmed">33275926</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor SC, Hurst B, Charlton CL, Bailey A, Kanji JN, McCarthy MK, et al.. A New SARS-CoV-2 Dual-Purpose Serology Test: Highly Accurate Infection Tracing and Neutralizing Antibody Response Detection. J Clin Microbiol. 2021;59(4). doi: 10.1128/JCM.02438-20</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.02438-20</ArticleId><ArticleId IdType="pmc">PMC8092720</ArticleId><ArticleId IdType="pubmed">33500361</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan CW, Chia WN, Qin X, Liu P, Chen MI, Tiu C, et al.. A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction. Nat Biotechnol. 2020;38(9):1073–8. doi: 10.1038/s41587-020-0631-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41587-020-0631-z</ArticleId><ArticleId IdType="pubmed">32704169</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohamed FF, Anhlan D, Schöfbänker M, Schreiber A, Classen N, Hensel A, et al.. Hypericum perforatum and Its Ingredients Hypericin and Pseudohypericin Demonstrate an Antiviral Activity against SARS-CoV-2. Pharmaceuticals. 2022;15(5):530. doi: 10.3390/ph15050530</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ph15050530</ArticleId><ArticleId IdType="pmc">PMC9146521</ArticleId><ArticleId IdType="pubmed">35631357</ArticleId></ArticleIdList></Reference><Reference><Citation>Berger Rentsch M, Zimmer G. A vesicular stomatitis virus replicon-based bioassay for the rapid and sensitive determination of multi-species type I interferon. PLoS One. 2011;6(10):e25858. doi: 10.1371/journal.pone.0025858</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0025858</ArticleId><ArticleId IdType="pmc">PMC3187809</ArticleId><ArticleId IdType="pubmed">21998709</ArticleId></ArticleIdList></Reference><Reference><Citation>Rambaut A, Holmes EC, O’Toole Á, Hill V, McCrone JT, Ruis C, et al.. A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology. Nature Microbiology. 2020;5(11):1403–7. doi: 10.1038/s41564-020-0770-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41564-020-0770-5</ArticleId><ArticleId IdType="pmc">PMC7610519</ArticleId><ArticleId IdType="pubmed">32669681</ArticleId></ArticleIdList></Reference><Reference><Citation>Hodcroft EB, Zuber M, Nadeau S, Vaughan TG, Crawford KHD, Althaus CL, et al.. Spread of a SARS-CoV-2 variant through Europe in the summer of 2020. Nature. 2021;595(7869):707–12. doi: 10.1038/s41586-021-03677-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03677-y</ArticleId><ArticleId IdType="pubmed">34098568</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen P, Datta G, Grace Li Y, Chien J, Price K, Chigutsa E, et al.. First-in-Human Study of Bamlanivimab in a Randomized Trial of Hospitalized Patients With COVID-19. Clin Pharmacol Ther. 2021;110(6):1467–77. doi: 10.1002/cpt.2405</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cpt.2405</ArticleId><ArticleId IdType="pmc">PMC8653186</ArticleId><ArticleId IdType="pubmed">34455583</ArticleId></ArticleIdList></Reference><Reference><Citation>Adams O, Andree M, Hermsen D, Lubke N, Timm J, Schaal H, et al.. Comparison of commercial SARS-CoV-2 surrogate neutralization assays with a full virus endpoint dilution neutralization test in two different cohorts. J Virol Methods. 2022;307:114569. doi: 10.1016/j.jviromet.2022.114569</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jviromet.2022.114569</ArticleId><ArticleId IdType="pmc">PMC9212436</ArticleId><ArticleId IdType="pubmed">35724697</ArticleId></ArticleIdList></Reference><Reference><Citation>Focosi D, Maggi F, Franchini M, McConnell S, Casadevall A. Analysis of Immune Escape Variants from Antibody-Based Therapeutics against COVID-19: A Systematic Review. Int J Mol Sci. 2021;23(1). doi: 10.3390/ijms23010029</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms23010029</ArticleId><ArticleId IdType="pmc">PMC8744556</ArticleId><ArticleId IdType="pubmed">35008446</ArticleId></ArticleIdList></Reference><Reference><Citation>Rockett R, Basile K, Maddocks S, Fong W, Agius JE, Johnson-Mackinnon J, et al.. Resistance Mutations in SARS-CoV-2 Delta Variant after Sotrovimab Use. N Engl J Med. 2022;386(15):1477–9. doi: 10.1056/NEJMc2120219</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2120219</ArticleId><ArticleId IdType="pmc">PMC8929376</ArticleId><ArticleId IdType="pubmed">35263515</ArticleId></ArticleIdList></Reference><Reference><Citation>Zahradník J, Marciano S, Shemesh M, Zoler E, Harari D, Chiaravalli J, et al.. SARS-CoV-2 variant prediction and antiviral drug design are enabled by RBD in vitro evolution. Nature Microbiology. 2021;6(9):1188–98. doi: 10.1038/s41564-021-00954-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41564-021-00954-4</ArticleId><ArticleId IdType="pubmed">34400835</ArticleId></ArticleIdList></Reference><Reference><Citation>Alenquer M, Ferreira F, Lousa D, Valerio M, Medina-Lopes M, Bergman ML, et al.. Signatures in SARS-CoV-2 spike protein conferring escape to neutralizing antibodies. PLoS Pathog. 2021;17(8):e1009772. doi: 10.1371/journal.ppat.1009772</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1009772</ArticleId><ArticleId IdType="pmc">PMC8341613</ArticleId><ArticleId IdType="pubmed">34352039</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor PC, Adams AC, Hufford MM, De La Torre I, Winthrop K, Gottlieb RL. Neutralizing monoclonal antibodies for treatment of COVID-19. Nature Reviews Immunology. 2021;21(6):382–93. doi: 10.1038/s41577-021-00542-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-021-00542-x</ArticleId><ArticleId IdType="pmc">PMC8054133</ArticleId><ArticleId IdType="pubmed">33875867</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang P, Nair MS, Liu L, Iketani S, Luo Y, Guo Y, et al.. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature. 2021;593(7857):130–5. doi: 10.1038/s41586-021-03398-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03398-2</ArticleId><ArticleId IdType="pubmed">33684923</ArticleId></ArticleIdList></Reference><Reference><Citation>Jensen B, Luebke N, Feldt T, Keitel V, Brandenburger T, Kindgen-Milles D, et al.. Emergence of the E484K mutation in SARS-COV-2-infected immunocompromised patients treated with bamlanivimab in Germany. Lancet Reg Health Eur. 2021;8:100164. doi: 10.1016/j.lanepe.2021.100164</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanepe.2021.100164</ArticleId><ArticleId IdType="pmc">PMC8278033</ArticleId><ArticleId IdType="pubmed">34278371</ArticleId></ArticleIdList></Reference><Reference><Citation>Starr TN, Greaney AJ, Addetia A, Hannon WW, Choudhary MC, Dingens AS, et al.. Prospective mapping of viral mutations that escape antibodies used to treat COVID-19. Science. 2021;371(6531):850–4. doi: 10.1126/science.abf9302</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abf9302</ArticleId><ArticleId IdType="pmc">PMC7963219</ArticleId><ArticleId IdType="pubmed">33495308</ArticleId></ArticleIdList></Reference><Reference><Citation>Starr TN, Greaney AJ, Dingens AS, Bloom JD. Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016. Cell Rep Med. 2021;2(4):100255. doi: 10.1016/j.xcrm.2021.100255</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2021.100255</ArticleId><ArticleId IdType="pmc">PMC8020059</ArticleId><ArticleId IdType="pubmed">33842902</ArticleId></ArticleIdList></Reference><Reference><Citation>Widera M, Wilhelm A, Hoehl S, Pallas C, Kohmer N, Wolf T, et al.. Limited Neutralization of Authentic Severe Acute Respiratory Syndrome Coronavirus 2 Variants Carrying E484K In Vitro. J Infect Dis. 2021;224(7):1109–14. doi: 10.1093/infdis/jiab355</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiab355</ArticleId><ArticleId IdType="pmc">PMC8344430</ArticleId><ArticleId IdType="pubmed">34223909</ArticleId></ArticleIdList></Reference><Reference><Citation>Quaranta EG, Fusaro A, Giussani E, D’Amico V, Varotto M, Pagliari M, et al.. SARS-CoV-2 intra-host evolution during prolonged infection in an immunocompromised patient. Int J Infect Dis. 2022;122:444–8. doi: 10.1016/j.ijid.2022.06.023</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2022.06.023</ArticleId><ArticleId IdType="pmc">PMC9212919</ArticleId><ArticleId IdType="pubmed">35724829</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen RE, Zhang X, Case JB, Winkler ES, Liu Y, VanBlargan LA, et al.. Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies. Nat Med. 2021;27(4):717–26. doi: 10.1038/s41591-021-01294-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01294-w</ArticleId><ArticleId IdType="pmc">PMC8058618</ArticleId><ArticleId IdType="pubmed">33664494</ArticleId></ArticleIdList></Reference><Reference><Citation>Bronstein Y, Adler A, Katash H, Halutz O, Herishanu Y, Levytskyi K. Evolution of spike mutations following antibody treatment in two immunocompromised patients with persistent COVID-19 infection. J Med Virol. 2022;94(3):1241–5. doi: 10.1002/jmv.27445</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27445</ArticleId><ArticleId IdType="pmc">PMC8661643</ArticleId><ArticleId IdType="pubmed">34755363</ArticleId></ArticleIdList></Reference><Reference><Citation>Scherer EM, Babiker A, Adelman MW, Allman B, Key A, Kleinhenz JM, et al.. SARS-CoV-2 Evolution and Immune Escape in Immunocompromised Patients. N Engl J Med. 2022;386(25):2436–8. doi: 10.1056/NEJMc2202861</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2202861</ArticleId><ArticleId IdType="pmc">PMC9202319</ArticleId><ArticleId IdType="pubmed">35675197</ArticleId></ArticleIdList></Reference><Reference><Citation>Halfmann PJ, Minor NR, Haddock Iii LA, Maddox R, Moreno GK, Braun KM, et al.. Evolution of a globally unique SARS-CoV-2 Spike E484T monoclonal antibody escape mutation in a persistently infected, immunocompromised individual. Virus Evol. 2023;9(2):veac104. doi: 10.1093/ve/veac104</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ve/veac104</ArticleId><ArticleId IdType="pmc">PMC10491860</ArticleId><ArticleId IdType="pubmed">37692895</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi B, Choudhary MC, Regan J, Sparks JA, Padera RF, Qiu X, et al.. Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host. N Engl J Med. 2020;383(23):2291–3. doi: 10.1056/NEJMc2031364</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2031364</ArticleId><ArticleId IdType="pmc">PMC7673303</ArticleId><ArticleId IdType="pubmed">33176080</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen L, Zody MC, Di Germanio C, Martinelli R, Mediavilla JR, Cunningham MH, et al.. Emergence of Multiple SARS-CoV-2 Antibody Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma Treatment. mSphere. 2021;6(4):e0048021. doi: 10.1128/mSphere.00480-21</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mSphere.00480-21</ArticleId><ArticleId IdType="pmc">PMC8386433</ArticleId><ArticleId IdType="pubmed">34431691</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez-Reiche AS, Alshammary H, Schaefer S, Patel G, Polanco J, Carreno JM, et al.. Sequential intrahost evolution and onward transmission of SARS-CoV-2 variants. Nat Commun. 2023;14(1):3235. doi: 10.1038/s41467-023-38867-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-38867-x</ArticleId><ArticleId IdType="pmc">PMC10239218</ArticleId><ArticleId IdType="pubmed">37270625</ArticleId></ArticleIdList></Reference><Reference><Citation>Khatamzas E, Antwerpen MH, Rehn A, Graf A, Hellmuth JC, Hollaus A, et al.. Accumulation of mutations in antibody and CD8 T cell epitopes in a B cell depleted lymphoma patient with chronic SARS-CoV-2 infection. Nat Commun. 2022;13(1):5586. doi: 10.1038/s41467-022-32772-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-32772-5</ArticleId><ArticleId IdType="pmc">PMC9508331</ArticleId><ArticleId IdType="pubmed">36151076</ArticleId></ArticleIdList></Reference><Reference><Citation>Peters JL, Fall A, Langerman SD, El Asmar M, Nakazawa M, Mustapha A, et al.. Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 Delta Variant Shedding in a Patient With AIDS: Case Report and Review of the Literature. Open Forum Infect Dis. 2022;9(9):ofac479. doi: 10.1093/ofid/ofac479</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofac479</ArticleId><ArticleId IdType="pmc">PMC9494428</ArticleId><ArticleId IdType="pubmed">36193230</ArticleId></ArticleIdList></Reference><Reference><Citation>Lustig G, Ganga Y, Rodel HE, Tegally H, Khairallah A, Jackson L, et al.. SARS-CoV-2 infection in immunosuppression evolves sub-lineages which independently accumulate neutralization escape mutations. Virus Evol. 2024;10(1):vead075. doi: 10.1093/ve/vead075</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ve/vead075</ArticleId><ArticleId IdType="pmc">PMC10868398</ArticleId><ArticleId IdType="pubmed">38361824</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JS, Yun KW, Jeong H, Kim B, Kim MJ, Park JH, et al.. SARS-CoV-2 shedding dynamics and transmission in immunosuppressed patients. Virulence. 2022;13(1):1242–51. doi: 10.1080/21505594.2022.2101198</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21505594.2022.2101198</ArticleId><ArticleId IdType="pmc">PMC9336477</ArticleId><ArticleId IdType="pubmed">35891618</ArticleId></ArticleIdList></Reference><Reference><Citation>Fournelle D, Mostefai F, Brunet-Ratnasingham E, Poujol R, Grenier JC, Galvez JH, et al.. Intra-Host Evolution Analyses in an Immunosuppressed Patient Supports SARS-CoV-2 Viral Reservoir Hypothesis. Viruses. 2024;16(3). doi: 10.3390/v16030342</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v16030342</ArticleId><ArticleId IdType="pmc">PMC10974702</ArticleId><ArticleId IdType="pubmed">38543708</ArticleId></ArticleIdList></Reference><Reference><Citation>Truong TT, Ryutov A, Pandey U, Yee R, Goldberg L, Bhojwani D, et al.. Increased viral variants in children and young adults with impaired humoral immunity and persistent SARS-CoV-2 infection: A consecutive case series. EBioMedicine. 2021;67:103355. doi: 10.1016/j.ebiom.2021.103355</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2021.103355</ArticleId><ArticleId IdType="pmc">PMC8072072</ArticleId><ArticleId IdType="pubmed">33915337</ArticleId></ArticleIdList></Reference><Reference><Citation>Ford ES, Simmons W, Karmarkar EN, Yoke LH, Braimah AB, Orozco JJ, et al.. Successful Treatment of Prolonged, Severe Coronavirus Disease 2019 Lower Respiratory Tract Disease in a B cell Acute Lymphoblastic Leukemia Patient With an Extended Course of Remdesivir and Nirmatrelvir/Ritonavir. Clin Infect Dis. 2023;76(5):926–9. doi: 10.1093/cid/ciac868</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac868</ArticleId><ArticleId IdType="pmc">PMC10226728</ArticleId><ArticleId IdType="pubmed">36326680</ArticleId></ArticleIdList></Reference><Reference><Citation>Gachoud D, Pillonel T, Tsilimidos G, Battolla D, Dumas D, Opota O, et al.. Antibody response and intra-host viral evolution after plasma therapy in COVID-19 patients pre-exposed or not to B-cell-depleting agents. Br J Haematol. 2022;199(4):549–59. doi: 10.1111/bjh.18450</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bjh.18450</ArticleId><ArticleId IdType="pmc">PMC9539045</ArticleId><ArticleId IdType="pubmed">36101920</ArticleId></ArticleIdList></Reference><Reference><Citation>Ko KKK, Yingtaweesittikul H, Tan TT, Wijaya L, Cao DY, Goh SS, et al.. Emergence of SARS-CoV-2 Spike Mutations during Prolonged Infection in Immunocompromised Hosts. Microbiol Spectr. 2022;10(3):e0079122. doi: 10.1128/spectrum.00791-22</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/spectrum.00791-22</ArticleId><ArticleId IdType="pmc">PMC9241677</ArticleId><ArticleId IdType="pubmed">35543562</ArticleId></ArticleIdList></Reference><Reference><Citation>Leung WF, Chorlton S, Tyson J, Al-Rawahi GN, Jassem AN, Prystajecky N, et al.. COVID-19 in an immunocompromised host: persistent shedding of viable SARS-CoV-2 and emergence of multiple mutations: a case report. Int J Infect Dis. 2022;114:178–82. doi: 10.1016/j.ijid.2021.10.045</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2021.10.045</ArticleId><ArticleId IdType="pmc">PMC8553657</ArticleId><ArticleId IdType="pubmed">34757008</ArticleId></ArticleIdList></Reference><Reference><Citation>Maponga TG, Jeffries M, Tegally H, Sutherland A, Wilkinson E, Lessells RJ, et al.. Persistent Severe Acute Respiratory Syndrome Coronavirus 2 Infection With accumulation of mutations in a patient with poorly controlled Human Immunodeficiency Virus infection. Clin Infect Dis. 2023;76(3):e522–e5. doi: 10.1093/cid/ciac548</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac548</ArticleId><ArticleId IdType="pmc">PMC9278209</ArticleId><ArticleId IdType="pubmed">35793242</ArticleId></ArticleIdList></Reference><Reference><Citation>Overbeck V, Taylor BP, Turcinovic J, Qiu X, Schaeffer B, Seitz S, et al.. Successful treatment of SARS-CoV-2 in an immunocompromised patient with persistent infection for 245 days: A case report. Heliyon. 2024;10(1):e23699. doi: 10.1016/j.heliyon.2023.e23699</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.heliyon.2023.e23699</ArticleId><ArticleId IdType="pmc">PMC10784163</ArticleId><ArticleId IdType="pubmed">38223743</ArticleId></ArticleIdList></Reference><Reference><Citation>Iketani S, Liu L, Guo Y, Liu L, Chan JF, Huang Y, et al.. Antibody evasion properties of SARS-CoV-2 Omicron sublineages. Nature. 2022;604(7906):553–6. doi: 10.1038/s41586-022-04594-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04594-4</ArticleId><ArticleId IdType="pmc">PMC9021018</ArticleId><ArticleId IdType="pubmed">35240676</ArticleId></ArticleIdList></Reference><Reference><Citation>Tegally H, Moir M, Everatt J, Giovanetti M, Scheepers C, Wilkinson E, et al.. Emergence of SARS-CoV-2 Omicron lineages BA.4 and BA.5 in South Africa. Nat Med. 2022;28(9):1785–90. doi: 10.1038/s41591-022-01911-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01911-2</ArticleId><ArticleId IdType="pmc">PMC9499863</ArticleId><ArticleId IdType="pubmed">35760080</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Q, Wu J, Nie J, Zhang L, Hao H, Liu S, et al.. The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity. Cell. 2020;182(5):1284–94.e9. doi: 10.1016/j.cell.2020.07.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.07.012</ArticleId><ArticleId IdType="pmc">PMC7366990</ArticleId><ArticleId IdType="pubmed">32730807</ArticleId></ArticleIdList></Reference><Reference><Citation>Lok S-M. An NTD supersite of attack. Cell Host &amp; Microbe. 2021;29(5):744–6. doi: 10.1016/j.chom.2021.04.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2021.04.010</ArticleId><ArticleId IdType="pmc">PMC8114578</ArticleId><ArticleId IdType="pubmed">33984277</ArticleId></ArticleIdList></Reference><Reference><Citation>McCallum M, De Marco A, Lempp FA, Tortorici MA, Pinto D, Walls AC, et al.. N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2. Cell. 2021;184(9):2332–47.e16. doi: 10.1016/j.cell.2021.03.028</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.03.028</ArticleId><ArticleId IdType="pmc">PMC7962585</ArticleId><ArticleId IdType="pubmed">33761326</ArticleId></ArticleIdList></Reference><Reference><Citation>Cerutti G, Guo Y, Zhou T, Gorman J, Lee M, Rapp M, et al.. Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite. Cell Host Microbe. 2021;29(5):819–33 e7. doi: 10.1016/j.chom.2021.03.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2021.03.005</ArticleId><ArticleId IdType="pmc">PMC7953435</ArticleId><ArticleId IdType="pubmed">33789084</ArticleId></ArticleIdList></Reference><Reference><Citation>McCarthy KR, Rennick LJ, Nambulli S, Robinson-McCarthy LR, Bain WG, Haidar G, et al.. Recurrent deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape. Science. 2021;371(6534):1139–42. doi: 10.1126/science.abf6950</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abf6950</ArticleId><ArticleId IdType="pmc">PMC7971772</ArticleId><ArticleId IdType="pubmed">33536258</ArticleId></ArticleIdList></Reference><Reference><Citation>Kemp SA, Collier DA, Datir RP, Ferreira IATM, Gayed S, Jahun A, et al.. SARS-CoV-2 evolution during treatment of chronic infection. Nature. 2021;592(7853):277–82. doi: 10.1038/s41586-021-03291-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03291-y</ArticleId><ArticleId IdType="pmc">PMC7610568</ArticleId><ArticleId IdType="pubmed">33545711</ArticleId></ArticleIdList></Reference><Reference><Citation>Spinicci M, Mazzoni A, Borchi B, Graziani L, Mazzetti M, Bartalesi F, et al.. AIDS patient with severe T cell depletion achieved control but not clearance of SARS-CoV-2 infection. Eur J Immunol. 2022;52(2):352–5. doi: 10.1002/eji.202149574</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/eji.202149574</ArticleId><ArticleId IdType="pmc">PMC9015404</ArticleId><ArticleId IdType="pubmed">34822185</ArticleId></ArticleIdList></Reference><Reference><Citation>Avanzato VA, Matson MJ, Seifert SN, Pryce R, Williamson BN, Anzick SL, et al.. Case Study: Prolonged Infectious SARS-CoV-2 Shedding from an Asymptomatic Immunocompromised Individual with Cancer. Cell. 2020;183(7):1901–12 e9. doi: 10.1016/j.cell.2020.10.049</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.10.049</ArticleId><ArticleId IdType="pmc">PMC7640888</ArticleId><ArticleId IdType="pubmed">33248470</ArticleId></ArticleIdList></Reference><Reference><Citation>Nussenblatt V, Roder AE, Das S, de Wit E, Youn JH, Banakis S, et al.. Yearlong COVID-19 Infection Reveals Within-Host Evolution of SARS-CoV-2 in a Patient With B-Cell Depletion. J Infect Dis. 2022;225(7):1118–23. doi: 10.1093/infdis/jiab622</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiab622</ArticleId><ArticleId IdType="pmc">PMC8755281</ArticleId><ArticleId IdType="pubmed">34940844</ArticleId></ArticleIdList></Reference><Reference><Citation>Taha Y, Wardle H, Evans AB, Hunter ER, Marr H, Osborne W, et al.. Persistent SARS-CoV-2 infection in patients with secondary antibody deficiency: successful clearance following combination casirivimab and imdevimab (REGN-COV2) monoclonal antibody therapy. Ann Clin Microbiol Antimicrob. 2021;20(1):85. doi: 10.1186/s12941-021-00491-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12941-021-00491-2</ArticleId><ArticleId IdType="pmc">PMC8717300</ArticleId><ArticleId IdType="pubmed">34969393</ArticleId></ArticleIdList></Reference><Reference><Citation>Monrad I, Sahlertz SR, Nielsen SSF, Pedersen LO, Petersen MS, Kobel CM, et al.. Persistent Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Immunocompromised Host Displaying Treatment Induced Viral Evolution. Open Forum Infect Dis. 2021;8(7):ofab295. doi: 10.1093/ofid/ofab295</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofab295</ArticleId><ArticleId IdType="pmc">PMC8244814</ArticleId><ArticleId IdType="pubmed">34258320</ArticleId></ArticleIdList></Reference><Reference><Citation>Hensley MK, Bain WG, Jacobs J, Nambulli S, Parikh U, Cillo A, et al.. Intractable Coronavirus Disease 2019 (COVID-19) and Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Replication in a Chimeric Antigen Receptor-Modified T-Cell Therapy Recipient: A Case Study. Clin Infect Dis. 2021;73(3):e815–e21. doi: 10.1093/cid/ciab072</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciab072</ArticleId><ArticleId IdType="pmc">PMC7929077</ArticleId><ArticleId IdType="pubmed">33507235</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaki L, Weigang S, Kern L, Kramme S, Wrobel AG, Grawitz AB, et al.. Total escape of SARS-CoV-2 from dual monoclonal antibody therapy in an immunocompromised patient. Nat Commun. 2023;14(1):1999. doi: 10.1038/s41467-023-37591-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-37591-w</ArticleId><ArticleId IdType="pmc">PMC10085998</ArticleId><ArticleId IdType="pubmed">37037847</ArticleId></ArticleIdList></Reference><Reference><Citation>Sonnleitner ST, Prelog M, Sonnleitner S, Hinterbichler E, Halbfurter H, Kopecky DBC, et al.. Cumulative SARS-CoV-2 mutations and corresponding changes in immunity in an immunocompromised patient indicate viral evolution within the host. Nature Communications. 2022;13(1). doi: 10.1038/s41467-022-30163-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-30163-4</ArticleId><ArticleId IdType="pmc">PMC9090742</ArticleId><ArticleId IdType="pubmed">35538074</ArticleId></ArticleIdList></Reference><Reference><Citation>Weigang S, Fuchs J, Zimmer G, Schnepf D, Kern L, Beer J, et al.. Within-host evolution of SARS-CoV-2 in an immunosuppressed COVID-19 patient as a source of immune escape variants. Nature Communications. 2021;12(1). doi: 10.1038/s41467-021-26602-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-26602-3</ArticleId><ArticleId IdType="pmc">PMC8568958</ArticleId><ArticleId IdType="pubmed">34737266</ArticleId></ArticleIdList></Reference><Reference><Citation>Borges V, Isidro J, Cunha M, Cochicho D, Martins L, Banha L, et al.. Long-Term Evolution of SARS-CoV-2 in an Immunocompromised Patient with Non-Hodgkin Lymphoma. mSphere. 2021;6(4):e0024421. doi: 10.1128/mSphere.00244-21</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mSphere.00244-21</ArticleId><ArticleId IdType="pmc">PMC8386466</ArticleId><ArticleId IdType="pubmed">34319130</ArticleId></ArticleIdList></Reference><Reference><Citation>Brandolini M, Zannoli S, Gatti G, Arfilli V, Cricca M, Dirani G, et al.. Viral Population Heterogeneity and Fluctuating Mutational Pattern during a Persistent SARS-CoV-2 Infection in an Immunocompromised Patient. Viruses. 2023;15(2). doi: 10.3390/v15020291</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v15020291</ArticleId><ArticleId IdType="pmc">PMC9962589</ArticleId><ArticleId IdType="pubmed">36851504</ArticleId></ArticleIdList></Reference><Reference><Citation>Heyer A, Gunther T, Robitaille A, Lutgehetmann M, Addo MM, Jarczak D, et al.. Remdesivir-induced emergence of SARS-CoV2 variants in patients with prolonged infection. Cell Rep Med. 2022;3(9):100735. doi: 10.1016/j.xcrm.2022.100735</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2022.100735</ArticleId><ArticleId IdType="pmc">PMC9378267</ArticleId><ArticleId IdType="pubmed">36075217</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheiblauer H, Nubling CM, Wolf T, Khodamoradi Y, Bellinghausen C, Sonntagbauer M, et al.. Antibody response to SARS-CoV-2 for more than one year—kinetics and persistence of detection are predominantly determined by avidity progression and test design. J Clin Virol. 2022;146:105052. doi: 10.1016/j.jcv.2021.105052</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2021.105052</ArticleId><ArticleId IdType="pmc">PMC8642248</ArticleId><ArticleId IdType="pubmed">34920374</ArticleId></ArticleIdList></Reference><Reference><Citation>Piccoli L, Park Y-J, Tortorici MA, Czudnochowski N, Walls AC, Beltramello M, et al.. Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology. Cell. 2020;183(4):1024–42.e21. doi: 10.1016/j.cell.2020.09.037</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.09.037</ArticleId><ArticleId IdType="pmc">PMC7494283</ArticleId><ArticleId IdType="pubmed">32991844</ArticleId></ArticleIdList></Reference><Reference><Citation>Qi H, Liu B, Wang X, Zhang L. The humoral response and antibodies against SARS-CoV-2 infection. Nat Immunol. 2022;23(7):1008–20. doi: 10.1038/s41590-022-01248-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-022-01248-5</ArticleId><ArticleId IdType="pubmed">35761083</ArticleId></ArticleIdList></Reference><Reference><Citation>Koerber N, Priller A, Yazici S, Bauer T, Cheng CC, Mijocevic H, et al.. Dynamics of spike-and nucleocapsid specific immunity during long-term follow-up and vaccination of SARS-CoV-2 convalescents. Nat Commun. 2022;13(1):153. doi: 10.1038/s41467-021-27649-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-27649-y</ArticleId><ArticleId IdType="pmc">PMC8748966</ArticleId><ArticleId IdType="pubmed">35013191</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazzoni A, Di Lauria N, Maggi L, Salvati L, Vanni A, Capone M, et al.. First-dose mRNA vaccination is sufficient to reactivate immunological memory to SARS-CoV-2 in subjects who have recovered from COVID-19. J Clin Invest. 2021;131(12). doi: 10.1172/JCI149150</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI149150</ArticleId><ArticleId IdType="pmc">PMC8203460</ArticleId><ArticleId IdType="pubmed">33939647</ArticleId></ArticleIdList></Reference><Reference><Citation>Karim F, Riou C, Bernstein M, Jule Z, Lustig G, van Graan S, et al.. Clearance of persistent SARS-CoV-2 associates with increased neutralizing antibodies in advanced HIV disease post-ART initiation. Nat Commun. 2024;15(1):2360. doi: 10.1038/s41467-024-46673-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-024-46673-2</ArticleId><ArticleId IdType="pmc">PMC10943233</ArticleId><ArticleId IdType="pubmed">38491050</ArticleId></ArticleIdList></Reference><Reference><Citation>Hale M, Netland J, Chen Y, Thouvenel CD, Smith KN, Rich LM, et al.. IgM antibodies derived from memory B cells are potent cross-variant neutralizers of SARS-CoV-2. J Exp Med. 2022;219(9). doi: 10.1084/jem.20220849</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20220849</ArticleId><ArticleId IdType="pmc">PMC9365875</ArticleId><ArticleId IdType="pubmed">35938988</ArticleId></ArticleIdList></Reference><Reference><Citation>Callegari I, Schneider M, Berloffa G, Muhlethaler T, Holdermann S, Galli E, et al.. Potent neutralization by monoclonal human IgM against SARS-CoV-2 is impaired by class switch. EMBO Rep. 2022;23(7):e53956. doi: 10.15252/embr.202153956</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embr.202153956</ArticleId><ArticleId IdType="pmc">PMC9253785</ArticleId><ArticleId IdType="pubmed">35548920</ArticleId></ArticleIdList></Reference><Reference><Citation>Ku Z, Xie X, Hinton PR, Liu X, Ye X, Muruato AE, et al.. Nasal delivery of an IgM offers broad protection from SARS-CoV-2 variants. Nature. 2021;595(7869):718–23. doi: 10.1038/s41586-021-03673-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03673-2</ArticleId><ArticleId IdType="pmc">PMC8742224</ArticleId><ArticleId IdType="pubmed">34082438</ArticleId></ArticleIdList></Reference><Reference><Citation>Gasser R, Cloutier M, Prevost J, Fink C, Ducas E, Ding S, et al.. Major role of IgM in the neutralizing activity of convalescent plasma against SARS-CoV-2. Cell Rep. 2021;34(9):108790. doi: 10.1016/j.celrep.2021.108790</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2021.108790</ArticleId><ArticleId IdType="pmc">PMC7874916</ArticleId><ArticleId IdType="pubmed">33596407</ArticleId></ArticleIdList></Reference><Reference><Citation>Kober C, Manni S, Wolff S, Barnes T, Mukherjee S, Vogel T, et al.. IgG3 and IgM Identified as Key to SARS-CoV-2 Neutralization in Convalescent Plasma Pools. PLoS One. 2022;17(1):e0262162. doi: 10.1371/journal.pone.0262162</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0262162</ArticleId><ArticleId IdType="pmc">PMC8726489</ArticleId><ArticleId IdType="pubmed">34982806</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnes CO, West AP Jr, Huey-Tubman KE, Hoffmann MAG, Sharaf NG, Hoffman PR, et al.. Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies. Cell. 2020;182(4):828–42 e16. doi: 10.1016/j.cell.2020.06.025</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.06.025</ArticleId><ArticleId IdType="pmc">PMC7311918</ArticleId><ArticleId IdType="pubmed">32645326</ArticleId></ArticleIdList></Reference><Reference><Citation>Callaway HM, Hastie KM, Schendel SL, Li H, Yu X, Shek J, et al.. Bivalent intra-spike binding provides durability against emergent Omicron lineages: Results from a global consortium. Cell Rep. 2023;42(1):112014. doi: 10.1016/j.celrep.2023.112014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2023.112014</ArticleId><ArticleId IdType="pmc">PMC9834171</ArticleId><ArticleId IdType="pubmed">36681898</ArticleId></ArticleIdList></Reference><Reference><Citation>Galimidi RP, Klein JS, Politzer MS, Bai S, Seaman MS, Nussenzweig MC, et al.. Intra-spike crosslinking overcomes antibody evasion by HIV-1. Cell. 2015;160(3):433–46. doi: 10.1016/j.cell.2015.01.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2015.01.016</ArticleId><ArticleId IdType="pmc">PMC4401576</ArticleId><ArticleId IdType="pubmed">25635457</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L, Iketani S, Guo Y, Chan JFW, Wang M, Liu L, et al.. Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2. Nature. 2022;602(7898):676–81. doi: 10.1038/s41586-021-04388-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-04388-0</ArticleId><ArticleId IdType="pubmed">35016198</ArticleId></ArticleIdList></Reference><Reference><Citation>Muecksch F, Weisblum Y, Barnes CO, Schmidt F, Schaefer-Babajew D, Wang Z, et al.. Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations. Immunity. 2021;54(8):1853–68.e7. doi: 10.1016/j.immuni.2021.07.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2021.07.008</ArticleId><ArticleId IdType="pmc">PMC8323339</ArticleId><ArticleId IdType="pubmed">34331873</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinto D, Park YJ, Beltramello M, Walls AC, Tortorici MA, Bianchi S, et al.. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature. 2020;583(7815):290–5. doi: 10.1038/s41586-020-2349-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2349-y</ArticleId><ArticleId IdType="pubmed">32422645</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>